ArticlePloS one2025
Tick saliva protein fraction inhibits breast cancer by decreasing cell viability and promoting apoptosis in vitro.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick saliva contains protein and non-protein bioactive molecules with potential therapeutic applications, including anticancer properties. In this study, the effects of protein and non-protein fractions of saliva from different tick species (Amblyomma spp. and Rhipicephalus sanguineus) at various concentrations (0.1-10 µg/mL) were tested on the viability, apoptosis, and necrosis of epithelial MDA-MB-231 breast cancer cells and spontaneously immortalized HaCaT cell control. Chemical composition of tick saliva from A. parvum and A. sculptum was characterized by proteomics analysis. Cell viability was assessed using a calcein-based fluorescence method. Hoechst staining quantified the total number of cells per well, while apoptosis and necrosis were evaluated using Hoescht and propidium iodide assays, respectively. On MDA-MB-231 cancer cells, the protein fraction from A. parvum and R. sanguineus significantly reduced cell viability at the highest concentration (10 µg/mL), whereas A. sculptum and non-protein fractions showed no significant effect. Hoechst staining revealed a significant reduction in cell attachment at 10 µg/mL for A. parvum and R. sanguineus. A modest apoptosis (3-8%) was induced by the protein fractions at concentrations as low as 0.1 µg/mL for R. sanguineus and 10 µg/mL for the non-protein fraction of A. sculptum. Necrosis was not observed, except for a slight increase (1%) with the protein fraction of R. sanguineus at 10 µg/mL. No effect of A. americanum tick saliva protein and non-protein fractions was observed in HaCaT control cells. The results of highly represented proteins identified in Amblyomma spp. correlated with effect of tick saliva protein fraction on cancer cells, highlighting the potential anticancer properties of tick saliva protein fraction, which can induce apoptosis and inhibit cell attachment in breast cancer cells. These findings provide a basis for future studies of tick saliva components as novel therapeutic agents and identifying active biomolecules and mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.